Sym-triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease

ACS Chemical Neuroscience

Volumn 4, Issue 2, 2013, Pages 339-349

  Veloso, Anthony J ^a   Dhar, Devjani ^a   Chow, Ari M ^a   Zhang, Biao ^a   Tang, Derek W F ^a   Ganesh, Hashwin V S ^a   Mikhaylichenko, Svetlana ^a   Brown, Ian R ^a   Kerman, Kagan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

acetylcholinesterase; Alzheimer's disease; amyloid ; butyrylcholinesterase; inhibitor; sym triazine

Indexed keywords

1 (DIMETHYLAMINO)PROPAN 2 YL 4 [(4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL)OXY]BENZOATE; 2,4,6 TRIS(4' CHLOROCARBONYLPHENOXY) 1,3,5 TRIAZINE; 2,4,6 TRIS[(1' DIMETHYLAMINO 2' PROPOXY) 4' CARBONYLPHENOXY]1,3,5 TRIAZINE; 2,4,6 TRIS[(2' DIMETHYLAMINO 1' ETHOXY) 4'] 1,3,5 TRIAZINE; 3 (DIMETHYLAMINO)PROPYL 4 [(4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL)OXY]BENZOATE; 3 [[4 [(4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL)OXY]BENZOYL]OXY]N,N,N,2 TRIMETHYLPROPAN 1 AMINIUM IODIDE; 3 [[4[(4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL)OXY]BENZOYL]OXY] N,N,N TRIMETHYLPROPAN 1 AMINIUM IODIDE; 3,3' [(4,4' [(6 METHOXY 1,3,5 TRIAZINE 2,4 DIYL)BIS(OXY)]BIS(BENZOYL)]BIS(OXY)]BIS(N,N,N TRIMETHYLPROPAN 1 AMINIUM)IODIDE; 4 [(4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL)OXY]BENZOIC ACID; 4 [(4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL)OXY]BENZOYL CHLORIDE; 4,4' [(6 METHOXY 1,3,5 TRIAZINE 2,4 DIYL)BIS(OXY)]DIBENZOIC ACID; 4,4' [(6 METHOXY 1,3,5 TRIAZINE 2,4 DIYL)BIS(OXY)]DIBENZOYL CHLORIDE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BIS[1 (DIMETHYLAMINO)PROPAN 2 YL]4,4' [(6 METHOXY 1,3,5 TRIAZINE 2,4 DIYL)BIS(OXY)]DIBENZOATE; BIS[3 (DIMETHYLAMINO)PROPAN YL]4,4' [(6 METHOXY 1,3,5 TRIAZINE 2,4 DIYL)BIS(OXY)]DIBENZOATE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BETA SHEET; CELL DIFFERENTIATION; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; HYDROPHOBICITY; NERVE CELL DIFFERENTIATION; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; PROTEIN TARGETING; STEADY STATE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; THIN LAYER CHROMATOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; BUTYRYLCHOLINESTERASE; CELL LINE; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSCOPY, ELECTRON, TRANSMISSION; NEURONS; TRIAZINES;

EID: 84874098413     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300171c     Document Type: Article

References (55)

1. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory Nature 440, 352-357
2. Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., and Mintun, M. A. (2005) Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory J. Neurosci. 25, 7709-7717
3. Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., Thompson, P. M., Huang, S. C., Satyamurthy, N., Phelps, M. E., and Barrio, J. R. (2006) PET of brain amyloid and tau in mild cognitive impairment New. Engl. J. Med. 355, 2652-2663
4. Davies, R. R., Hodges, J. R., Kril, J. J., Patterson, K., Halliday, G. M., and Xuereb, J. H. (2005) The pathological basis of semantic dementia Brain 128, 1984-1995
5. Querfurth, H. W. and LaFerla, F. M. (2010) Mechanisms of disease: Alzheimer's disease New. Engl. J. Med. 362, 329-344
6. Zheng, L., Kagedal, K., Dehvari, N., Benedikz, E., Cowburn, R., Jan, M., and Terman, A. (2009) Oxidative stress induces macroautophagy of amyloid beta-protein and ensuing apoptosis Free Radical Biol. Med. 46, 422-429
7. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., and Glabe, C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers J. Biol. Chem. 280, 17294-17300
8. Qin, L. Y., Liu, Y. X., Cooper, C., Liu, B., Wilson, B., and Hong, J. S. (2002) Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species J. Neurochem. 83, 973-983
9. Geng, J., Li, M., Ren, J. S., Wang, E. B., and Qu, X. G. (2011) Polyoxometalates as inhibitors of the aggregation of amyloid beta peptides associated with Alzheimer's disease Angew. Chem., Int. Ed. 50, 4184-4188
10. Wang, H.-Y., Ying, Y.-L., Li, Y., Kraatz, H.-B., and Long, Y.-T. (2011) Nanopore analysis of beta-amyloid peptide aggregation transition induced by small molecules Anal. Chem. 83, 1746-1752
11. Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., de Llano, S. R. M., Liu, E., Koller, M., Gregg, K. M., Schenk, D., Black, R., and Grundman, M. (2010) (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol. 9, 363-372
12. Siemers, E. R., Friedrich, S., Dean, R. A., Gonzales, C. R., Farlow, M. R., Paul, S. M., and DeMattos, R. B. (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease Clin. Neuropharmacol. 33, 67-73
13. Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., and Oremus, M. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline Ann. Intern. Med. 148, 379-397
14. Schliebs, R. and Arendt, T. (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease J. Neural. Trans. 113, 1625-1644
15. Daiello, L. A. (2007) Current issues in dementia pharmacotherapy Am. J. Manag. Care 13, S198-S202
16. Delrieu, J., Piau, A., Caillaud, C., Voisin, T., and Vellas, B. (2011) Managing cognitive dysfunction through the continuum of Alzheimer's disease role of pharmacotherapy CNS Drugs 25, 213-226
17. Bassil, N. and Grossberg, G. T. (2009) Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease CNS Drugs 23, 293-307
18. Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I., and Lewis, K. W. (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease J. Am. Med. Assoc. 271, 992-998
19. Inestrosa, N. C., Alvarez, A., Perez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., and Garrido, J. (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme Neuron 16, 881-891
20. Onor, M. L., Trevisiol, M., and Aguglia, E. (2007) Rivastigmine in the treatment of Alzheimer's disease: An update Clin. Interventions Aging 2, 17-32
21. Lane, R. M., Kivipelto, M., and Greig, N. H. (2004) Acetylcholinesterase and its inhibition in Alzheimer disease Clin. Neuropharmacol. 27, 141-149
22. Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., and Recanatini, M. (2003) 3-(4-{Benzyl(methyl)amino methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: A dual function lead for Alzheimer's disease therapy J. Med. Chem. 46, 2279-2282
23. Dantoine, T., Auriacombe, S., Sarazin, M., Becker, H., Pere, J. J., and Bourdeix, I. (2006) Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment Int. J. Clin. Pract. 60, 110-118
24. Morphy, R. and Rankovic, Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 48, 6523-6543
25. Bolognesi, M. L., Cavalli, A., and Melchiorre, C. (2009) Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease Neurotherapeutics 6, 152-162
26. Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., and Melchiorre, C. (2008) Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 51, 347-372
27. Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., Tumiatti, V., Andrisano, V., Mellor, I. R., and Melchiorre, C. (2008) Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: A promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 51, 4381-4384
28. Bolognesi, M. L., Bartolini, M., Rosini, M., Andrisano, V., and Melchiorre, C. (2009) Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action Bioorg. Med. Chem. Lett. 19, 4312-4315
29. Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., and Rampa, A. (2008) Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorg. Med. Chem. Lett. 18, 423-426
30. Choi, K. Y., Swierczewska, M., Lee, S., and Chen, X. (2012) Protease-activated drug development Theranostics 2, 156-178
31. Elderfield, R. C. (1961) Heterocyclic Compounds, in Polycyclic Compounds Containing Two Hetero Atoms in Different Rings (Elderfield, R. C., Ed.), 1 st ed., John Wiley and Sons, New York.
32. Gupta, R. R., Kumar, M., and Gupta, V. (1999) In Heterocyclic Chemistry (Gupta, R. R., Ed.), 1 st ed., Springer, New York.
33. Mur, V. I. (1964) 2,4,6-Trichloro-1,3,5-triazine (cyunaryl chloride) and its future applications Russ. Chem. Rev. 33, 92-103
34. Blotny, G. (2006) Recent applications of 2,4,6-trichloro-1,3,5-triazine and its derivatives in organic synthesis Tetrahedron 62, 9507-9522
35. Thurston, J. T., Dudley, J. R., Kaiser, D. W., Hechenbleikner, I., Schaefer, F. C., and Holmhansen, D. (1951) Cyunaric chloride derivatives 0.1. Aminochloro-s-triazines J. Am. Chem. Soc. 73, 2981-2983
36. Afonso, C. A. M., Lourenco, N. M. T., and Rosatella, A. D. (2006) Synthesis of 2,4,6-tri-substituted-1,3,5-triazines Molecules 11, 81-102
37. Dudley, J. R., Thurston, J. T., Schaefer, F. C., Holmhansen, D., Hull, C. J., and Adams, P. (1951) Cyunaric chloride derivatives 0.3. Alkoxy-s-triazines J. Am. Chem. Soc. 73, 2986-2990
38. Pogosyan, G. M., Zaplishnyi, V. I., Khachatryan, M. A., and Atashyan, S. M. (1986) Synthesis of an iron-ammonia complex of an acid containing s-triazine and production of thermostable adhesives from it J. App. Chem. USSR 59, 588-593
39. Sklyarskii, L. S., Akopyan, L. L., Ogandzhanyan, L. M., Stepanyan, V. N., Zaplishny, V. N., and Pogosyan, G. M. (1988) Polymerklei Scientific-Industrial Enterprisess USSR, U.S.S.R. Published Patent Application SU 1409629.
40. Ellman, G. L., Courtney, K. D., Andres, V., and Featherstone, R. M. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7, 88
41. Rampa, A., Bisi, A., Belluti, F., Gobbi, S., Valenti, P., Andrisano, V., Cavrini, V., Cavalli, A., and Recanatini, M. (2000) Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: Molecular modeling, synthesis and kinetic evaluation of 11H-indeno-1,2-b -quinolin-10-ylamine derivatives Bioorg. Med. Chem. 8, 497-506
42. Jackisch, R., Foerster, S., Kammerer, M., Rothmaier, A. K., Ehret, A., Zentner, J., and Feuerstein, T. J. (2009) Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex J. Alzheimer's Dis. 16, 635-647
43. Barak, D., Ordentlich, A., Bromberg, A., Kronman, C., Marcus, D., Lazar, A., Ariel, N., Velan, B., and Shafferman, A. (1995) Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite Biochemistry 34, 15444-15452
44. Massoulie, J., Sussman, J., Bon, S., and Silman, I. (1993) Cholinergic Function and Dysfunction, in Structure and Functions of Acetylcholinesterase and Butyrylcholinesterase (Cuello, A. C., Ed.), 1 st ed., pp 139-146, Elsevier Science Publishers, Amsterdam.
45. Sun, Y., Zhang, G., Hawkes, C. A., Shaw, J. E., McLaurin, J., and Nitz, M. (2008) Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation Bioorgan. Med. Chem. 16, 7177-7184
46. Wong, H. E., Qi, W., Choi, H.-M., Fernandez, E. J., and Kwon, I. (2011) A safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregates ACS Chem. Neurosci. 2, 645-657
47. Estrada, L. D. and Soto, C. (2007) Disrupting beta-amyloid aggregation for Alzheimer disease treatment Curr. Top. Med. Chem. 7, 115-126
48. Haass, C. and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nature Rev. Mol. Cell Biol. 8, 101-112
49. Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H., Neugebauer, K., and Wanker, E. E. (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity Proc. Natl. Acad. Sci. U.S.A. 107, 7710-7715
50. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., and Wanker, E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15, 558-566
51. Meng, X., Munishkina, L. A., Fink, A. L., and Uversky, V. N. (2009) Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation Biochemistry 48, 8206-8224
52. LeVine, H. (2004) The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide J. Alzheimer's Dis. 6, 303-314
53. Chi, E. Y., Frey, S. L., Winans, A., Lam, K. L. H., Kjaer, K., Majewski, J., and Lee, K. Y. C. (2010) Amyloid-beta fibrillogenesis seeded by interface-induced peptide misfolding and self-assembly Biophys. J. 98, 2299-2308
54. Xie, H. R., Hu, L. S., and Li, G. Y. (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease Chinese Med. J. 123, 1086-1092
55. Chow, A. M. and Brown, I. R. (2007) Induction of heat shock proteins in differentiated human and rodent neurons by celastrol Cell Stress Chaperones 12, 237-244